Skip to main content
Georgia Cancer Info Logo
Donate
Georgia Cancer Info Logo
About Georgia CORENews & HappeningsWays to Give
Advancing ResearchExplore Clinical TrialsCollaboration Opportunities
ScreeningGeorgia Genetics ProgramEducation & NavigationSurvivorship

Check your hereditary breast & ovarian cancer risk with our easy Genetic Screening Tool.

Start risk assessment
Search ResourcesFind Cancer Centers
Donate
Georgia Cancer Info Logo

Contact us

+1-404-523-8735info@georgiacancerinfo.org
999 Peachtree St NE, Suite 400Atlanta, GA 30309

Sign up for news and announcements

  • Home
  • About
  • Contact
  • Facebook
  • LinkedIn
  • Instagram

© 2005 - 2026 Georgia Center for Oncology Research and Education. All Rights Reserved.

PrivacyTerms & Conditions
Amelia B. Zelnak, MD, MSc
  1. About Us/
  2. Amelia B. Zelnak, MD, MSc

Amelia B. Zelnak, MD, MSc

Hematologist, Managing Partner, Atlanta Cancer Care

Dr. Zelnak is a board-certified hematologist and medical oncologist with expertise in treating solid tumors, blood cancers and hematologic disorders. She completed training in internal medicine and was a fellow in hematology and oncology at the Emory University School of Medicine.

Prior to joining Atlanta Cancer Care, Dr. Zelnak was part of the faculty at Emory University in the Department of Hematology and Medical Oncology. Currently she is a member of the Northside Hospital Breast Care Committee, Northside Hospital Cancer Institute (NHCI) Breast Research Work Group, NHCI Research Advisory Committee, Susan G. Komen Atlanta Advisory Council, and the Georgia NCORP Clinical Research Team.

Dr. Zelnak is a managing partner of Atlanta Cancer Care.

Amelia B. Zelnak, MD, MSc

Keep up to date with Georgia CORE on LinkedIn

Real stories from patients, survivors, and advocates across Georgia.

Follow on LinkedIn
Oct. stakeholder session: Should Georgia have a cancer clinical trials roundtable?

Day 2 of an impressive convening of Georgia CORE partners representing the cancer research, care provider, patient navigation and advocacy communities. Each stakeholder session was an opportunity for these groups to come together and discuss how to carry the recommendations forward of the Georgia House Study Committee on Access to Cancer Care on day 1; and the state of cancer clinical trials in Georgia on day 2. Be on the look out for the forthcoming report of these impactful two days!